Where does AIMD stock trade?

Ainos Inc. (AIMD) is listed on NASDAQ.

What sector and industry is AIMD in?

Ainos Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

What companies are similar to AIMD?

Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AIMD side-by-side with any of them on Quantisnow.

How can I track AIMD on Quantisnow?

Quantisnow aggregates Ainos Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AIMD to receive live email and push alerts on every new disclosure.

AIMD

NASDAQ

Ainos Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations

$1.92-0.04 (-2.04%)

News25/Ratings0

Price$1.92+0.39 (+25.49%)

2026-03-112026-06-12

News · 26 weeks51+33%

2025-12-212026-06-14

Mix3290d

Insider15(47%)
Market13(41%)
SEC Filings4(13%)

Latest news

25 items

5dINSIDER
Director Chiang Yao-Chung bought $7,175 worth of shares (3,500 units at $2.05) (SEC Form 4)
4 - Ainos, Inc. (0001014763) (Issuer)
6dNEWS
Ainos Releases 2026 Mid-Year CEO Letter to Shareholders
Building the Olfactory Layer of Physical AIHighlighting Progress Across Semiconductor Manufacturing, Healthcare Infrastructure and Physical AI Applications HOUSTON, TX / ACCESS Newswire / June 8, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in AI-powered scent digitization and Smell AI technologies, today released its 2026 Mid-Year Letter to Shareholders from Chairman, President and Chief Executive Officer Eddy Tsai.2026 First Half HighlightsCommercial MomentumReported 499% year-over-year revenue growth during fiscal year 2025.Continued transforming Ainos from a biotechnology-focused company into a technology platform company centered on Smell AI and E
8dINSIDER
Director Chiang Yao-Chung bought $4,260 worth of shares (2,000 units at $2.13) (SEC Form 4)
4 - Ainos, Inc. (0001014763) (Issuer)
9dNEWS
VASRO Research Highlights Ainos Smell AI Expansion into Emergency Department Operations
HOUSTON, TX / ACCESS Newswire / June 5, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today highlighted a recent report published by VASRO GmbH ("VASRO"), discussing the expansion of the Company's AI Nose platform into emergency department operations and the continued growth of its Smell ID data across diverse real-world environments.In the report, VASRO reviews Ainos' recently announced research program at one of Asia's leading academic medical centers, where AI Nose is being deployed within a live emergency department environment to evaluate environmental sc
11dNEWS
Zacks SCR Discusses Ainos' Expansion of Smell AI into Healthcare Infrastructure Through NTUH Study
HOUSTON, TX / ACCESS Newswire / June 3, 2026 / Ainos, Inc. (NASDAQ:AIMD, AIMDW)) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today announced that Zacks Small-Cap Research ("Zacks SCR") has published a new article discussing Ainos' recently announced healthcare infrastructure study at National Taiwan University Hospital ("NTUH").The article reviews Ainos' initiative to deploy AI Nose in a live emergency department environment and explores the potential role of Smell AI in environmental monitoring, healthcare infrastructure, and artificial intelligence applications.According to the article, the Smell AI st
12dINSIDER
Director Chiang Yao-Chung bought $575 worth of shares (250 units at $2.30) (SEC Form 4)
4 - Ainos, Inc. (0001014763) (Issuer)
13dNEWS
Ainos Launches Smell AI Study at National Taiwan University Hospital for ER Overcrowding and Respiratory Infection Risk Analysis
AI Nose Expands from Semiconductor Facilities into Frontline Healthcare Infrastructure HOUSTON, TX / ACCESS Newswire / June 1, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today announced the launch of a research program at National Taiwan University Hospital ("NTUH"), one of Asia's leading academic medical centers, to deploy AI Nose inside a live emergency department environment for intelligent environmental monitoring, ER overcrowding early warning, and respiratory infection risk analysis.The program aims to expand Smell AI, powered by AI Nose, inside a rea
15dINSIDER
Director Chiang Yao-Chung bought $4,000 worth of shares (2,000 units at $2.00) (SEC Form 4)
4 - Ainos, Inc. (0001014763) (Issuer)
17dINSIDER
Director Lee Ting-Chuan sold $208,977 worth of shares (109,988 units at $1.90), decreasing direct ownership by 12% to 807,417 units (SEC Form 4) to satisfy tax liability
4 - Ainos, Inc. (0001014763) (Issuer)
17dINSIDER
Large owner Taiwan Carbon Nano Technology Corp sold $96,760 worth of shares (41,000 units at $2.36), decreasing direct ownership by 4% to 948,925 units (SEC Form 4) (withholding obligation)
4 - Ainos, Inc. (0001014763) (Issuer)
17dINSIDER
Director Tsai Chun-Jung sold $53,510 worth of shares (28,800 units at $1.86), decreasing direct ownership by 4% to 658,199 units (SEC Form 4) (withholding tax)
4 - Ainos, Inc. (0001014763) (Issuer)
18dINSIDER
Director Lee Ting-Chuan sold $28,644 worth of shares (18,302 units at $1.57), decreasing direct ownership by 2% to 917,405 units (SEC Form 4) to satisfy withholding obligation
4 - Ainos, Inc. (0001014763) (Issuer)
24dINSIDER
Director Chiang Yao-Chung bought $4,521 worth of shares (2,700 units at $1.67) (SEC Form 4)
4 - Ainos, Inc. (0001014763) (Issuer)
25dNEWS
VASRO Research Highlights Ainos AI Nose Commercialization Progress and Semiconductor Industry Shift Toward AI-Driven Environmental Intelligence
HOUSTON, TX / ACCESS Newswire / May 20, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today highlighted a new research update published by VASRO GmbH discussing AI Nose, the Company's AI-powered scent digitization and Smell AI platform, and ongoing commercialization progress across semiconductor manufacturing, robotics integration, and healthcare infrastructure markets. The report notes that the Company is advancing initiatives intended to support potential second half 2026 revenue generation.The VASRO report characterizes Ainos' first quarter of 2026 as a "commercialization-build quarter." According to the report, Ainos continues progressing key initiatives invol
27dNEWS
Zacks Small-Cap Research Highlights Ainos' Smell AI Commercialization
HOUSTON, TX / ACCESS Newswire / May 18, 2026 / Ainos, Inc. (NASDAQ:AIMD, AIMDW)) ("Ainos" or the "Company") today highlighted a recent report published by Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research, discussing the Company's AI Nose platform and ongoing commercialization activities.The report discusses Ainos' ongoing transition from a healthcare-focused biotechnology company into a company developing AI-powered scent digitization technologies centered on AI Nose, the Company's proprietary AI-powered scent digitization platform. According to the report, AI Nose is designed to convert scent and volatile organic compound ("VOC") signals into machine-readable
31dSEC
SEC Form 10-Q filed by Ainos Inc.
10-Q - Ainos, Inc. (0001014763) (Filer)
31dSEC
Ainos Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Ainos, Inc. (0001014763) (Filer)
31dNEWS
Ainos Reports First Quarter 2026 Financial Results and Highlights Smell AI Execution Across Semiconductors and Healthcare Infrastructure Markets
HOUSTON, TX / ACCESS Newswire / May 13, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced financial results for the first quarter ended March 31, 2026 and provided a business update on recent execution progress for AI Nose across semiconductors and healthcare infrastructure applications .During the first quarter of 2026, Ainos continued executing its commercialization priorities for AI Nose across industrial infrastructure environments while continuing to expand its Smell ID datasets and refine its Smell Language Model ("SLM") through deployment and pilot activities."Our first quarter progress reflects a continued transition from validation activities
34dNEWS
Ainos Updates Standard Industrial Classification Code to Reflect Smell AI Business Focus
Updated classification reflects Ainos' transition toward AI-powered scent intelligence commercialization HOUSTON, TX / ACCESS Newswire / May 11, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it updated its Standard Industrial Classification ("SIC") code from SIC 2834 - Pharmaceutical Preparations to SIC 3577 - Computer Peripheral Equipment, NEC. We believe the updated classification reflects Ainos' operational evolution and commercialization focus on AI-powered sensing, industrial AI applications, and Smell AI technologies driven by AI Nose, the Company's proprietary AI-powered scent digitization platform.AI Nose converts volatile organic comp
37dINSIDER
Director Chiang Yao-Chung bought $219 worth of shares (129 units at $1.70) (SEC Form 4)
4 - Ainos, Inc. (0001014763) (Issuer)
43dINSIDER
Director Chiang Yao-Chung bought $511 worth of shares (300 units at $1.70) (SEC Form 4)
4 - Ainos, Inc. (0001014763) (Issuer)
57dINSIDER
SEC Form 4 filed by Tsai Chun-Jung
4 - Ainos, Inc. (0001014763) (Issuer)
57dINSIDER
SEC Form 4 filed by Tsai Chun-Hsien
4 - Ainos, Inc. (0001014763) (Issuer)
57dINSIDER
SEC Form 4 filed by Lee Ting-Chuan
4 - Ainos, Inc. (0001014763) (Issuer)
58dNEWS
VASRO: Ainos Expands Smell AI from Industrials into Healthcare Infrastructure, Reinforcing AI Infrastructure Positioning and Multi-Vertical Scalability
2026 Identified as a Key Scale-Up Phase with Expanding Market Verticals and Accelerating Data Flywheel HOUSTON, TX / ACCESS Newswire / April 17, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) today highlighted the continued expansion of its Smell AI deployments, powered by AI Nose, across semiconductor, robotics, and healthcare infrastructure, highlighted by recent third-party research published by VASRO GmbH. The report underscores Smell AI's progression from isolated sensing applications to scalable multi-domain AI perception platform and identifies 2026 as a key scale-up year as Ainos moves toward deployment and repeatable revenue generation.The report highlights growing visibility into S

AIMD FAQ

4 questions

Where does AIMD stock trade?
Ainos Inc. (AIMD) is listed on NASDAQ.
What sector and industry is AIMD in?
Ainos Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
What companies are similar to AIMD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AIMD side-by-side with any of them on Quantisnow.
How can I track AIMD on Quantisnow?
Quantisnow aggregates Ainos Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AIMD to receive live email and push alerts on every new disclosure.